238 related articles for article (PubMed ID: 22976995)
1. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.
Toyooka S; Kiura K; Shien K; Katsui K; Hotta K; Kanazawa S; Date H; Miyoshi S
Interact Cardiovasc Thorac Surg; 2012 Dec; 15(6):954-60. PubMed ID: 22976995
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis.
Toyooka S; Kiura K; Takemoto M; Oto T; Takigawa N; Fujiwara T; Miyoshi S; Date H
Interact Cardiovasc Thorac Surg; 2012 May; 14(5):565-9. PubMed ID: 22354091
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer.
Cohen C; Pop D; Venissac N; Poudenx M; Otto J; Castelnau O; Mouroux J
Thorac Cardiovasc Surg; 2018 Mar; 66(2):129-134. PubMed ID: 28992652
[TBL] [Abstract][Full Text] [Related]
7. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of proliferative indices in surgically resected IIIA-N2 non-small cell lung cancer after induction chemotherapy.
Corzani R; Luzzi L; Spina D; Voltolini L; Paladini P; Ghiribelli C; Ghisalberti M; Borrelli R; Meniconi F; Monaci N; Gotti G
J Cardiovasc Surg (Torino); 2017 Oct; 58(5):763-769. PubMed ID: 24740119
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy of radiotherapy between postoperative mediastinal lymph node recurrence and stage III disease in non-small cell lung cancer patients.
Imai H; Murakami H; Yoshino R; Mori K; Sumita K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Harada H; Naito T; Kaira K; Tomizawa Y; Ohde Y; Matsuura M; Endo M; Saito R; Nakajima T; Takahashi T
J BUON; 2016; 21(2):333-40. PubMed ID: 27273942
[TBL] [Abstract][Full Text] [Related]
10. Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the results justify the risk?
Steger V; Walker T; Mustafi M; Lehrach K; Kyriss T; Veit S; Friedel G; Walles T
Interact Cardiovasc Thorac Surg; 2012 Dec; 15(6):948-53. PubMed ID: 22997251
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
[TBL] [Abstract][Full Text] [Related]
12. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.
Amini A; Correa AM; Komaki R; Chang JY; Tsao AS; Roth JA; Swisher SG; Rice DC; Vaporciyan AA; Lin SH
Ann Thorac Surg; 2012 Sep; 94(3):914-20. PubMed ID: 22819472
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
14. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
[TBL] [Abstract][Full Text] [Related]
15. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
[TBL] [Abstract][Full Text] [Related]
16. Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer.
Tsuchiya T; Matsumoto K; Miyazaki T; Yamaguchi H; Yamazaki T; Sano I; Fukuoka J; Nakamura Y; Yamasaki N; Nagayasu T
Gen Thorac Cardiovasc Surg; 2019 Jun; 67(6):537-543. PubMed ID: 30673966
[TBL] [Abstract][Full Text] [Related]
17. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
Fournel P; Vergnenégre A; Robinet G; Léna H; Gervais R; Le Caer H; Souquet PJ; Chavaillon JM; Bozonnat MC; Daurès JP; Chouaid C; Martel-Lafay I;
Eur J Cancer; 2016 Jan; 52():181-7. PubMed ID: 26689864
[TBL] [Abstract][Full Text] [Related]
18. Major Pathologic Response after Induction Therapy Has a Long-Term Impact on Survival and Tumor Recurrence in Stage IIIA/B Locally Advanced NSCLC.
Schreiner W; Dudek W; Rieker RJ; Lettmaier S; Fietkau R; Sirbu H
Thorac Cardiovasc Surg; 2020 Oct; 68(7):639-645. PubMed ID: 30808023
[TBL] [Abstract][Full Text] [Related]
19. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
